These results imply that compound 5 k may possibly treat NSCLC by regulating the NF‐κB/STAT3 signaling pathways and decreasing cancer cell proliferation (Zhi et al. 2022). The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.